These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 46047)

  • 21. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore.
    Lancet; 1975 Dec; 2(7945):1105-9. PubMed ID: 53598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study.
    Kobashi Y; Matsushima T
    Respiration; 2007; 74(4):394-400. PubMed ID: 16954651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
    Long MW; Snider DE; Farer LS
    Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco.
    Slutkin G; Schecter GF; Hopewell PC
    Am Rev Respir Dis; 1988 Dec; 138(6):1622-4. PubMed ID: 3144221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia.
    Singla R; Al-Sharif N; Al-Sayegh MO; Osman MM; Shaikh MA
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
    S Afr Med J; 1996 Aug; 86(8):960-5. PubMed ID: 8823423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
    Lancet; 1974 Nov; 2(7889):1100-6. PubMed ID: 4139405
    [No Abstract]   [Full Text] [Related]  

  • 29. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association.
    Br J Dis Chest; 1981 Apr; 75(2):141-53. PubMed ID: 7023526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A triple regimen of streptomycin, isoniazid and ethambutol or rifampicin, isoniazid and ethambutol in untreated cases of pulmonary tuberculosis. 3.
    Oka S; Sasaki M; Kobayashi T; Matsuda T
    Sci Rep Res Inst Tohoku Univ Med; 1972 Sep; 19(2):84-8. PubMed ID: 4649627
    [No Abstract]   [Full Text] [Related]  

  • 31. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
    Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC;
    Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
    Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
    Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
    Jindani A; Nunn AJ; Enarson DA
    Lancet; 2004 Oct 2-8; 364(9441):1244-51. PubMed ID: 15464185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Present status of chemotherapy for tuberculosis.
    Grosset JH
    Rev Infect Dis; 1989; 11 Suppl 2():S347-52. PubMed ID: 2652251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrashort-course chemotherapy for culture-negative pulmonary tuberculosis--a qualified success.
    Cowie RL; Langton ME; Escreet BC
    S Afr Med J; 1985 Dec; 68(12):879-80. PubMed ID: 4071345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-course chemotherapy of pulmonary tuberculosis in pneumoconiotic patients.
    Lin TP; Suo J; Lee CN; Lee JJ; Yang SP
    Am Rev Respir Dis; 1987 Oct; 136(4):808-10. PubMed ID: 3310770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1988 May; 137(5):1147-50. PubMed ID: 2904237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
    Mitchison DA; Nunn AJ
    Am Rev Respir Dis; 1986 Mar; 133(3):423-30. PubMed ID: 2420242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
    Snider DE; Zierski M; Graczyk J; Bek E; Farer LS
    Eur J Respir Dis; 1986 Jan; 68(1):12-8. PubMed ID: 3512281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.